期刊文献+

替格瑞洛和辛伐他汀早期联合治疗不稳定性心绞痛疗效观察 被引量:12

Observation of the clinical therapeutic effect of ticagrelor and simvastatin in the early treatment of unstable Angina
下载PDF
导出
摘要 目的观察替格瑞洛和辛伐他汀早期联合治疗不稳定性心绞痛的临床疗效。方法选择2014年1月~2015年5月在本院就诊的78例不稳定性心绞痛患者,随机分为治疗组(n=40)、对照组(n=38)。两组均常规应用硝酸酯类、β-受体阻滞剂和阿司匹林等药物治疗,治疗组予替格瑞洛和辛伐他汀治疗。随访3个月,观察两组的临床疗效和主要心脏不良事件。结果治疗组治疗有效率92.50%,对照组治疗有效率71.05%,两组比较差异有统计学意义(P〈0.05);治疗组主要心脏不良事件发生率12.50%,对照组主要心脏不良事件发生率28.95%,两组比较差异有统计学意义(P〈0.05)。结论替格瑞洛和辛伐他汀早期联合治疗不稳定性心绞痛可明显提高治疗有效率,减少主要心脏不良事件的发生。 Objective To observe the clinical therapeutic effect of ticagreclor and simvastatin in the early treatment of unstable angina. Methods A total of 78 unstable angina patients admitted in the first affiliated hospital of Guangdong Pharmaceutical University from January 2014 to May 2015 were randomly divided into treatment group(n=40) and con- trol group(n=38). Two groups were given drugs of nitrates,beta-blocker and aspirin. While the treatment group was ad- ditional treated with ticagreclor and simvastatin. After three months follow-up, the clinical therapeutic effect and the events of major adverse cardiac were observed in both groups. Results For the treatment group and the control group, the improvement of clinical therapeutic effect was(92.50% vs 71.05%,P〈0.05). The events of major adverse cardiac was significant (12.50% vs 28.95%,P〈0.05). Conclusion Associated with ticagreclorl and simvastatin to early treat unstable angina can improve the clinical therapeutic effect and decrease the major adverse cardiac events significantly.
出处 《中国现代医生》 2015年第29期79-81,85,共4页 China Modern Doctor
关键词 替格瑞洛 辛伐他汀 不稳定性心绞痛 Ticagrelor Simvastatin Unstable angina
  • 相关文献

参考文献15

  • 1Teng R,Mitchell PD,Butler K. Lack of significant food ef- fect on the pharmacokinetics of ticagrelor in the healthy volunteers[J]. J Ctin Pharm Ther, 2012,37 (4) : 464-468.
  • 2Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of tica- grelor in healthy volunteers[J]. BRJ Clin Pharmacol,2010, 70(1) :67-77.
  • 3Jneid H,Anderson,JL Wright RS,et al. 2012ACCF/AHA focused update of the guideline for the mangement of pa- tients with unstable angina/non-st-elevation myocardial infarction (updting the 2007 guigeling and replacing the 2011 focused update) :A report of the American college of cardiology foundation/American heart association task force on practice guideline[J]. Jam Coil Cardiol, 2012,60 (7) : 645-681.
  • 4刘淑芳.低分子肝素治疗急性冠状动脉综合征患者的疗效观察[J].医学研究通讯,2005,34(3):36-37. 被引量:8
  • 5陈灏珠,钟南山,陆再英.内科学[M].第8版.北京:人民卫生出版社,2013:3.
  • 6Lombo B,Diez JG. Ticagrelor:The evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardial events in the patient with acute coronary syndromes[J]. Core Evid, 2011,12(6) : 31-42.
  • 7Anderson JL,Adams. CD,Antman EM,et al. 2012 ACC/A- HA focused update incorporated into the ACC/AHA 2007 guidelines for the mangemant of patients with the unstable angina/no-st-elevation myocardial infarction a report of the american college of cardiology foundation/American Association Task Force on Practice Guidelines[J]. J Amcoll Cardiol,2013,61 (23) :347.
  • 8Beeker RC,Bassand JP, Budaj A,et al. Bleeding compli- cations with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the platelet inhibition and patient Out- comes(PLATO) trial[J]. Eurheart J,2011 (32) : 2933-2944.
  • 9蔡宏宇,高航.急性冠状动脉综合征药物治疗进展[J].中国心血管病研究,2008,6(9):718-720. 被引量:4
  • 10Wouters CW,Wever KE,Bronckers I,et al. Short-term statin treatment does not prevent isehemia and reperfu sion-induced endothelial dysfunction in humans[J]. J Car- diovasc Pharmacol, 2012,59 ( 1 ) : 22-28.

二级参考文献32

  • 1江一清.不稳定心绞痛的机理和防治新进展[J].中国急救医学,1995,15(4):48-55. 被引量:79
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5222
  • 3[1]Claudia M,Anthony M,John FM.What causes acute coronary syndromes:applying Koch's postulates.Atheroaclerosis,2005,179:1.
  • 4[2]Vila V,Martinez-Sale V,Reganon E,et al.Effects of unfractionatedand low molecular weight heparins on plasma level of hemostatic factorsin patients with acute coronary syndromes.Hacmatologica,2001,86:729-734.
  • 5[3]Goodman SG,Cohen M,Bigonzi F,et al.Randomized trial of low molecular weight heparin(enoxaparin)versus unfractionated heparin for unstable coronary artery disease:one year results of the ESSENCE Study.Ettlcacy and safety of Subcutaneous Enoxapacinin Non-O-Wave Coronary Events.J Am Coll Cardiol,2000,36:693-698.
  • 6[4]Antman EM,Cohen M,Radley D,et al.For the TIMI II B and ESSENCE Investigatom.Assessment 0f the treatment effect of enoxaparin for unstable angina non-Q-wave myocardial infarction.TIMI II B ESSENCE meta-analysis.Circulafion,1999,100:1602-1608.
  • 7[5]Wong GC,Giughano RP,Antman EM.Use of low-molecularweight heparin in the management of acute coronary artery syndrome and percutaneous CO ronsry intervention.JAMA,2003,289:331-342.
  • 8[7]许俊堂,胡大一,丛玉隆.心血管血栓的溶栓及抗凝疗法.北京:人民卫生出版社,2000:22.
  • 9[8]OASIS-2 Investigators.Effects of recombinant hirudin(lepirodin)compared with heparin on death,myocardial infarction,refractory angina,and revaacularisation procedures in patients with acute myocardial ischaemia without ST elevation:a randomised trial.Lancet,1999,353:429-438.
  • 10[10]MeCarty D,Walsh SJ,Adgey AA.Current management issues in angiua.Practitioner,2001,245:377-380.

共引文献303

同被引文献64

引证文献12

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部